Structure-Activity Relationship of Quaternary Acetylcholinesterase Inhibitors - Outlook for Early Myasthenia Gravis Treatment

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|17|17|1810-1824

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.17, Iss.17, 2010-06, pp. : 1810-1824

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treat myasthenia gravis with individualized doses of acetylcholinesterase inhibitors and immunomodulators

By  

Drugs & Therapy Perspectives, Vol. 27, Iss. 7, 2011-07 ,pp. : 18-21

Adis International

Access to resources Recommend Favorite

Structure-Activity Relationship for the Reactivators of Acetylcholinesterase Inhibited by Nerve Agent VX

By  

Medicinal Chemistry, Vol. 9, Iss. 5, 2013-08 ,pp. : 689-693

Bentham Science Publishers

Access to resources Recommend Favorite

Immunomodulatory treatment for myasthenia gravis

By  

Inpharma, Vol. 1, Iss. 1283, 2001-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Treatment strategies for myasthenia gravis: an update

By Díaz-Manera Jordi   Rojas García Ricard   Illa Isabel  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 13, 2012-09 ,pp. : 1873-1883

Informa Healthcare

Access to resources Recommend Favorite

Treatment of Myasthenia Gravis: Focus on Pyridostigmine

By Maggi Lorenzo   Mantegazza Renato  

Clinical Drug Investigation, Vol. 31, Iss. 10, 2011-10 ,pp. : 691-701

Adis International

Access to resources Recommend Favorite